- Home
- Products
- Customized ADCs
- ST8SIA1
- Anti-ST8SIA1 (Mitumomab)-MC-MMAF ADC
Anti-ST8SIA1 (Mitumomab)-MC-MMAF ADC (CAT#: ADC-W-1780)
This ADC product is comprised of an anti-ST8SIA1 monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- ST8SIA1
- Alternative Names
- ST8SIA1; ST8 alpha-N-acetyl-neuraminide alpha-2, 8-sialyltransferase 1; sialyltransferase 8 (alpha N acetylneuraminate: alpha 2, 8 sialytransferase, GD3 synthase) A , SIAT8, SIAT8A; alpha-N-acetylneuraminide alpha-2, 8-sialyltransferase; ST8Sia I; ganglioside GD3 synthase; ganglioside GT3 synthase; sialytransferase St8Sia I; alpha-2, 8-sialyltransferase 8A; disialoganglioside (GD3) synthase; ganglioside-specific alpha-2, 8-polysialyltransferase; sialyltransferase 8 (alpha-N-acetylneuraminate: alpha-2, 8-sialytransferase, GD3 synthase) A; sialyltransferase 8A (alpha-N-acetylneuraminate: alpha-2, 8-sialyltransferase, GD3 synthase); GD3S; SIAT8; SIAT8A; SIAT8-A; ST8SiaI;
- Target Entrez Gene ID
- 6489
- Target UniProt ID
- Q92185
- Overview
- Gangliosides are membrane-bound glycosphingolipids containing sialic acid. Ganglioside GD3 is known to be important for cell adhesion and growth of cultured malignant cells. The protein encoded by this gene is a type II membrane protein that catalyzes the transfer of sialic acid from CMP-sialic acid to GM3 to produce gangliosides GD3 and GT3. The encoded protein may be found in the Golgi apparatus and is a member of glycosyltransferase family 29. Alternatively spliced transcript variants have been found for this gene.
- Overview
- Humanized Anti-ST8SIA1 IgG2b-kappa antibody, Mitumomab
- Generic name
- Mitumomab
- Host animal
- Mouse
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-TNFSF11 (Denosumab)-SMCC-DM1 ADC (CAT#: ADC-W-2234)
- Anti-ERBB2 (Trastuzumab)-Mc-Dol15 ADC (CAT#: ADC-W-410)
- Anti-RTN4 (Ozanezumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1746)
- Anti-HGF (Rilotumumab)-SMCC-DM1 ADC (CAT#: ADC-W-1184)
- Anti-IL1B (Gevokizumab)-MC-MMAF ADC (CAT#: ADC-W-1330)
- Anti-CD40LG (Ruplizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-919)
- Anti-C-kit (9P3)-SPDB-DM4 ADC (CAT#: ADC-W-077)
- Anti-CD3E (Foralumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-840)
- Anti-C. diff toxin B (Bezlotoxumab)-SPDB-DM4 ADC (CAT#: ADC-W-2061)
- Anti-CD28 (lulizumab pegol)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-2335)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-1780. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-1782 | Anti-ST8SIA1 (Mitumomab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-1783 | Anti-ST8SIA1 (Mitumomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-1779 | Anti-ST8SIA1 (Mitumomab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-1781 | Anti-ST8SIA1 (Mitumomab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-1778 | Anti-ST8SIA1 (Mitumomab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-322 | Anti-CD19 (clone hBU12)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-114 | Anti-CD33 (clone m2H12)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-2606 | Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-515 | Anti-EGFR (ABT-806)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-537 | Anti-TPBG-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2544 | Anti-CD44 (Bivatuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2591 | Anti-EGFR (Cetuximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-AA-064 | Anti-HIgG(Fab)-C-MMAF ADC | Cleavable linkers | MMAF |
| ADC-W-2567 | Anti-MUC16 (Sofituzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
